The Metabolomics of Airway Diseases, Including Copd, Asthma and Cystic Fibrosis

The Metabolomics of Airway Diseases, Including Copd, Asthma and Cystic Fibrosis Publisher Pubmed

Nobakht M Gh BF^{1, 4} ; Aliannejad R² ; Rezaeitavirani M¹ ; Taheri S³ ; Oskouie AA⁴

Show Affiliations

1. Faculty of Paramedical Sciences, Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2. Pulmonary Department, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
3. Chemistry and Chemical Engineering Research Center of Iran, Tehran, Iran
4. Faculty of Paramedical Sciences, Department of Basic Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: Biomarkers Published:2015

Abstract

Chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis (CF) are characterized by airway obstruction and an inflammatory process. Reaching early diagnosis and discrimination of subtypes of these respiratory diseases are quite a challenging task than other chronic illnesses. Metabolomics is the study of metabolic pathways and the measurement of unique biochemical molecules generated in a living system. In the last decade, metabolomics has already proved to be useful for the characterization of several pathological conditions and offers promises as a clinical tool. In this article, we review the current state of the metabolomics of COPD, asthma and CF with a focus on the different methods and instrumentation being used for the discovery of biomarkers in research and translation into clinic as diagnostic aids for the choice of patient-specific therapies. © 2014 Informa UK Ltd.

2. Omics Insights Into Cancer Histology; Metabolomics and Proteomics Approach, Clinical Biochemistry (2020)

3. Metabolomics Signature of Cardiovascular Disease in Patients With Diabetes, a Narrative Review, Journal of Diabetes and Metabolic Disorders (2023)

Experts (# of related papers)

View all Related Experts

Bagher Larijani (2)

Farideh Razi (1)

Style	Citing Format
MLA	Nobakht M Gh BF, et al.. "The Metabolomics of Airway Diseases, Including Copd, Asthma and Cystic Fibrosis." Biomarkers, vol. 20, no. 1, 2015, pp. 5-16.
APA	Nobakht M Gh BF, Aliannejad R, Rezaeitavirani M, Taheri S, Oskouie AA (2015). The Metabolomics of Airway Diseases, Including Copd, Asthma and Cystic Fibrosis. Biomarkers, 20(1), 5-16.
Chicago	Nobakht M Gh BF, Aliannejad R, Rezaeitavirani M, Taheri S, Oskouie AA. "The Metabolomics of Airway Diseases, Including Copd, Asthma and Cystic Fibrosis." Biomarkers 20, no. 1 (2015): 5-16.
Harvard	Nobakht M Gh BF et al. (2015) 'The Metabolomics of Airway Diseases, Including Copd, Asthma and Cystic Fibrosis', Biomarkers, 20(1), pp. 5-16.
Vancouver	Nobakht M Gh BF, Aliannejad R, Rezaeitavirani M, Taheri S, Oskouie AA. The Metabolomics of Airway Diseases, Including Copd, Asthma and Cystic Fibrosis. Biomarkers. 2015;20(1):5-16.
BibTex	@article{ author = {Nobakht M Gh BF and Aliannejad R and Rezaeitavirani M and Taheri S and Oskouie AA}, title = {The Metabolomics of Airway Diseases, Including Copd, Asthma and Cystic Fibrosis}, journal = {Biomarkers}, volume = {20}, number = {1}, pages = {5-16}, year = {2015} }
RIS	TY - JOUR AU - Nobakht M Gh BF AU - Aliannejad R AU - Rezaeitavirani M AU - Taheri S AU - Oskouie AA TI - The Metabolomics of Airway Diseases, Including Copd, Asthma and Cystic Fibrosis JO - Biomarkers VL - 20 IS - 1 SP - 5 EP - 16 PY - 2015 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract